Articles

Poll

Podcasts

Slideshows

Videos

A phase 2a trial of provides data detailing the effects of inaxaplin, a small molecule APOL1 inhibitor, on urinary protein-to-creatinine ratio in people with focal segmental glomerulosclerosis and two APOL1 variants. 

Inaxaplin Shows Promise for APOL1-Mediated FSGS in Phase 2a Trial

At ACC.23, our editorial team sat down with a pair of leaders in cardiometabolic health to get their perspective on the growing intersectionality of cardiovascular and chronic kidney disease and how patients have been the beneficiaries of this growing recognition. 

How Patients Benefit from Growing Intersectionality of Renal and Cardiovascular Diseases

Results from the NOSTONE trial suggest the incidence of recurrence did not differ among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25 mg, or 50 mg or once-daily placebo. 

Hydrochlorothiazide Shows Lack of Effect on Prevention of Recurrent Kidney Stones

The company announced more feedback from the FDA after receiving a Complete Response Letter last March.

Akebia Continues FDA Appeal for Vadadustat as CKD Anemia Treatment

Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis. 

Daprodustat Receives FDA Approval for Anemia Caused by CKD on Dialysis

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease. 

Kirsten Johansen, MD: Improving the Quality of Life for CKD Patients With Anemia

The 2022 updated guidelines includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease. 

KDIGO Updates Clinical Practice Guideline for Diabetes Management in CKD

There was no significant differences in creatinine or estimated glomerular filtration rate between the readmission group and the no readmission group. 

Ileostomy Formation Results in Deterioration of Renal Function

Results from the REGARDS study suggest traditional CKD risk factors were associated with higher risk of incident CKD and eGFR decline in Black individuals, compared to White individuals. 

Traditional Risk Factors for Incident CKD Yielded Greater Racial Disparities  

The topline phase 2b data shows both 75 mg and 150 mg doses of atacicept resulted in a 31% mean reduction in proteinuria. 

Atacicept Reduces Proteinuria in IgAN Patients

Chronic Kidney Disease

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Nephrology